Acotiamide is a drug approved in Japan for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia.
More Information Supplier PageAcotiamide is a drug approved in Japan for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia.
More Information Supplier PageAcotiamide is a drug approved in Japan for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia.
More Information Supplier PageUF010 is a potent and selective HADC inhibitor with IC50 ~0.06 ??M, 0.1 ??M, 0.5 ??M and 1.5 ??M for HDACs 3, 2, 1 and 8, respectively. It has > 6-fold selectivity over other HDACs.
More Information Supplier PageUF010 is a potent and selective HADC inhibitor with IC50 ~0.06 ??M, 0.1 ??M, 0.5 ??M and 1.5 ??M for HDACs 3, 2, 1 and 8, respectively. It has > 6-fold selectivity over other HDACs.
More Information Supplier PageUF010 is a potent and selective HADC inhibitor with IC50 ~0.06 ??M, 0.1 ??M, 0.5 ??M and 1.5 ??M for HDACs 3, 2, 1 and 8, respectively. It has > 6-fold selectivity over other HDACs.
More Information Supplier PageIsavuconazole is the active component of the new azole antifungal agent BAL8557, exhibits MIC(50)s/MIC(90)s ranged from 0.002/0.004 mg/liter for C. albicans to 0.25/0.5 mg/liter for C. glabrata.
More Information Supplier PageIsavuconazole is the active component of the new azole antifungal agent BAL8557, exhibits MIC(50)s/MIC(90)s ranged from 0.002/0.004 mg/liter for C. albicans to 0.25/0.5 mg/liter for C. glabrata.
More Information Supplier Page
